Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker.

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

OSAKA, Japan - Photo taken Sept. 3 shows the headquarters of Dainippon Sumitomo Pharma Co. in Osaka. The company said the same day it has agreed to buy out Sepracor Inc., a Massachusetts-based pharmaceutical maker, for around $2.6 billion in an attempt to tap into the U.S. market.

Operator estimates 300 bil. yen to scrap Monju reactor over 30 yrs

Operator estimates 300 bil. yen to scrap Monju reactor over 30 yrs

File photo taken in January 2016 shows the trouble-prone Monju fast-breeder reactor in Tsuruga, Japan. Science minister Hiroshi Hase said on Feb. 16 that the operator of Monju had estimated the cost to scrap the experimental reactor over 30 years at around 300 billion yen ($2.6 billion). (Kyodo) ==Kyodo

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker. (Kyodo)

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

OSAKA, Japan - Photo taken Sept. 3 shows the headquarters of Dainippon Sumitomo Pharma Co. in Osaka. The company said the same day it has agreed to buy out Sepracor Inc., a Massachusetts-based pharmaceutical maker, for around $2.6 billion in an attempt to tap into the U.S. market. (Kyodo)